Praxis Precision Medicines Inc [PRAX] stock is trading at $178.08, down -3.01%. An important factor to consider is whether the stock is rising or falling in short-term value. The PRAX shares have gain 3.32% over the last week, with a monthly amount glided 210.51%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Chardan Capital Markets started tracking the stock with Buy rating on May 07, 2025, and set its price target to $80. On March 03, 2025, H.C. Wainwright reiterated its Buy rating and revised its price target to $105 on the stock. Deutsche Bank started tracking the stock assigning a Buy rating and suggested a price target of $111 on February 11, 2025. Oppenheimer initiated its recommendation with a Outperform and recommended $134 as its price target on August 05, 2024. Needham started tracking with a Buy rating for this stock on June 24, 2024, and assigned it a price target of $145. In a note dated June 18, 2024, Guggenheim initiated an Buy rating and provided a target price of $155 on this stock.
Praxis Precision Medicines Inc [PRAX] stock has fluctuated between $26.70 and $206.71 over the past year. Currently, Wall Street analysts expect the stock to reach $277 within the next 12 months. Praxis Precision Medicines Inc [NASDAQ: PRAX] shares were valued at $178.08 at the most recent close of the market. An investor can expect a potential return of 55.55% based on the average PRAX price forecast.
Analyzing the PRAX fundamentals
Praxis Precision Medicines Inc [NASDAQ:PRAX] reported sales of 7.46M for the trailing twelve months, which represents a drop of -100.00%. Gross Profit Margin for this corporation currently stands at 0.99% with Operating Profit Margin at -34.98%, Pretax Profit Margin comes in at -32.33%, and Net Profit Margin reading is -32.33%. To continue investigating profitability, this company’s Return on Assets is posted at -0.55, Equity is -0.6 and Total Capital is -0.67. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 175.38 points at the first support level, and at 172.69 for the second support level. However, for the 1st resistance point, the stock is sitting at 182.46, and for the 2nd resistance point, it is at 186.85.
Ratios To Look Out For
For context, Praxis Precision Medicines Inc’s Current Ratio is 5.18. On the other hand, the Quick Ratio is 5.18, and the Cash Ratio is 3.24. Considering the valuation of this stock, the price to sales ratio is 596.95, the price to book ratio is 10.97.
